Phase II Trial of Androgen Suppression for 6 Months Combined With External Beam Radiotherapy (EBRT) With Brachytherapy (BT) Boost for Intermediate Risk Prostate Cancer.
Phase of Trial: Phase II
Latest Information Update: 20 Jul 2016
At a glance
- Drugs Bicalutamide (Primary) ; Flutamide (Primary) ; Goserelin (Primary) ; Leuprorelin (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 01 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 11 Apr 2011 Planned end date (Mar 2012) added as reported by ClinicalTrials.gov.